In vitro Tolerance of Staphylococcus haemolyticus and Candida albicans Biofilms to Dalbavancin and Anidulafungin

Abstract

Background: Concerns about infections resulting from bacterial biofilm formation in invasive devices such as catheters and prostheses are becoming widespread in the public health domain. Staphylococcus haemolyticus, a coagulase-negative bacterium, and Candida albicans, a yeast, have become recurrent pathogens of these diseases because their presence in these devices enhances the likelihood of infection. It is believed that these microorganisms produce biofilms, which complicate treatment and slow the patient´s recuperation. Dalbavancin is a semisynthetic, lipoglycopeptide-class antibiotic utilized as an anti-infective agent to break down gram-positive bacteria biofilms. Anidulafungin is an echinocandin class antifungal medication that works very well against resistant yeast strains and removes biofilms.

Objective: This study aims to examine the anti-infective agents´ tolerance to the biofilms of Staphylococcus haemolyticus and Candida albicans.

Methods: Polymicrobial biofilms were grown in a CDC Biofilm Reactor (CBR) for use in in vitro experiments.

Results: When dalbavancin maintained its antibiotic activities against Staphylococcus haemolyticus in comparison with their activity against the sessile forms, the antifungal anidulafungin lost efficacy in eliminating Candida albicans.

Conclusion: The planktonic forms of microbes are examined in relation to the tolerance to these anti-infective drugs.